Procter & Gamble (P&G), the Cincinnati-based consumer-products powerhouse, reported its fiscal second-quarter earnings, exceeding Wall Street's projections and raising its full-year profit forecast. The company's adjusted earnings stood at $1.84 per share for the period ending December 31, up from $1.59 per share a year ago. This surpasses the average analyst expectation of $1.70 per share according to FactSet.
P&G recorded a 3% increase in sales, reaching $21.44 billion, slightly below Wall Street's estimate of $21.48 billion. However, when considering organic sales growth, which excludes foreign exchange fluctuations, acquisitions, and divestitures, the company achieved a notable 4% increase.
Looking ahead to fiscal 2024, P&G updated its adjusted per-share earnings growth forecast to be within the range of 8%-9%. This corresponds to an anticipated earnings per share range of $6.37 to $6.43, compared to the previous growth forecast of 6% to 9%. Analysts are currently projecting a full-year adjusted profit of $6.41 per share.
P&G also maintained its outlook for full-year sales growth, expecting a range of 2% to 4%, as well as organic sales growth between 4% and 5%.
The positive performance of P&G demonstrates its continued strength in the consumer-products market, exceeding expectations and showcasing its ability to deliver consistent growth.
Primark Expects Strong Performance for Fiscal 2024
U.K. Stocks Experience Marginal Decline
Our Latest News
AB InBev Earnings Preview 2023
An overview of Anheuser-Busch InBev's upcoming fourth-quarter and full-year earnings forecast, key factors affecting the brewing industry, and strategic respons...
Trump White House Official Peter Navarro Convicted of Contempt of Congress Charges
Peter Navarro, a former official in the Trump White House, has been convicted of contempt of Congress charges for refusing to cooperate with a congressional inv...
Galecto Discontinues Lead Product Candidate in Chronic Lung Disease Study
Galecto has halted the development of inhaled GB0139 for IPF treatment following Phase 2b study failure. The focus now turns to severe liver diseases.